Prostate Cancer: Genomic Insights - July 31, 2015

Genomics|Features|Prostate Cancer

Prostate Cancer

Prostate Cancer: Genomic Insights - July 31, 2015

CDC and Related Info

• Prostate cancer
• What are the risk factors?
• Genes reported in relation to prostate cancer, including genomewide association studies via theHuGE Navigator

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
H Ross-Adams et al,Ebiomedicine, July 2015

Five subtypes of prostate cancer identified, paving way for more personalized treatments, by AE Cha, Washington Post, Jul 30

A family history of lethal prostate cancer and risk of aggressive prostate cancer in patients undergoing radical prostatectomy.
Raheem OA et al. Sci Rep 2015 510544

Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
Antonarakis ES et al. JAMA Oncology, June 4, 2015

Two susceptibility loci identified for prostate cancer aggressiveness.
Berndt SI et al. Nat Commun 2015 6889

Replication of a genetic variant for prostate cancer-specific mortality.
Penney KL et al. Prostate Cancer Prostatic Dis. 2015 May 5.

Widespread telomere instability in prostatic lesions.
Tu LiRen et al. Mol. Carcinog. 2015 Apr 27.

Genomic predictors of outcome in prostate cancer.
Boström PJ et al. Eur. Urol. 2015 Apr 23.

Loss of WAVE1 gene defines a subtype of lethal prostate cancer.
Sowalsky AG et al. Oncotarget 2015 Mar 31.

The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer.
Bancroft EK et al. Psychooncology 2015 Apr 14.

Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy.
Cheng J et al. Prostate Cancer Prostatic Dis. 2015 Apr 14.

Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men.
Devaney J M et al. Epigenetics 2015 Apr 3. (4) 319-28

The protective effect of methylenetetrahydrofolate reductase C677T polymorphism against prostate cancer risk: Evidence from 23 case-control studies.
Guo Shanqi et al. Gene 2015 Jul 1. (1) 90-5

Risk analysis of prostate cancer in PRACTICAL, a multinational consortium, using 25 known prostate cancer susceptibility loci.
Amin Al OA et al. Cancer Epidemiol. Biomarkers Prev. 2015 Apr 2.

Polymorphisms of genes involved in glucose and energy metabolic pathways and prostate cancer: Interplay with metformin.
Murtola TJ et al. Eur. Urol. 2015 Mar 25.

Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.
Yadav SS et al. Urol. Oncol. 2015 Mar 16.

Prostate Cancer Screening: Can we use genetics for stratification - February 19, 2015

A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation.
Grill Sonja et al. J Clin Epidemiol 2015 Jan 14.

Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.
Yen Amy Ming-Fang et al. Prostate 2015 Feb 14.

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. 
Nora Pashayan et al. Genetics in Medicine, January 8, 2015

Prostate cancer risk prediction based on complete prostate cancer family history. 
Albright F et al., Prostate. 2014 Nov 18.

Prostate Cancer Screening: Role for Genetics? - December 4, 2014

The problem with prostate screening, by Richard J. Ablin, New York Times, Nov 25

Recent insights

Prostate cancer risk prediction based on complete prostate cancer family history 
Albright F, et al. Prostate 2014 Nov

Prevention and early detection of prostate cancer.
Cuzick J, et al. Lancet Oncol. 2014 Oct;15(11):e484-92.

Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. 
Davis JW. BJU Int. 2014 Sep;114(3):320-2

Copy number alteration burden predicts prostate cancer relapse.
Hieronymus H, et al. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44

"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer.
Bancroft EK, et al. Fam Cancer. 2014 Dec;13(4):625-35

Prostate Cancer: Genomics and Screening - September 18, 2014

CDC information: Prostate cancer screening- A prostate specific antigen (PSA) test may find a prostate health problem, but treatment can cause serious side effects. Learn about prostate cancer and talk to your doctor before you decide to get tested or treated for prostate cancer

The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)-based screening for prostate cancer

Talking to men about PSA testing,  by Barak Gaster, New York Times, Aug 19  

CDC information: Risk factors for prostate cancer include genetics and family health history

NCI information: Genetics of prostate cancer (PDQ)

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
Al Olama AA, et al. Nat Genet. 2014 Sep 14

New genetic variants indicate risk for prostate cancer: international study, Medical News Today, Sep 17

Did you know? 995 genes have been reported in relation to prostate cancer risk and outcomes, including 81 genomewide association studies. To find out more, visit the HuGE Navigator

Incorporating genomics into breast and prostate cancer screening: assessing the implications. 
Susmita Chowdhury MD, MPhil et al. Genetics in Medicine, 2013